This company has been marked as potentially delisted and may not be actively trading. NASDAQ:KNTE Kinnate Biopharma (KNTE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Kinnate Biopharma Stock (NASDAQ:KNTE) 30 days 90 days 365 days Advanced Chart Get Kinnate Biopharma alerts:Sign Up Key Stats Today's Range$2.65▼$2.6550-Day Range$2.45▼$2.6652-Week Range$1.04▼$7.18VolumeN/AAverage Volume418,678 shsMarket Capitalization$125.13 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC. Read More Receive KNTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kinnate Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KNTE Stock News HeadlinesKinetic Engineering Ltd (KNTE)July 24, 2024 | investing.comKNTE Kinnate Biopharma Inc.April 4, 2024 | seekingalpha.comA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.September 15 at 2:00 AM | Investors Alley (Ad)KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEMarch 13, 2024 | businesswire.comKinnate Biopharma sells rights of exarafenib to Pierre Fabre laboratoriesMarch 1, 2024 | msn.comKinnate Biopharma Sells Exarafenib To Pierre Fabre Laboratories - Quick FactsMarch 1, 2024 | markets.businessinsider.comKinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre LaboratoriesMarch 1, 2024 | prnewswire.comKinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre LaboratoriesMarch 1, 2024 | globenewswire.comSee More Headlines KNTE Stock Analysis - Frequently Asked Questions How were Kinnate Biopharma's earnings last quarter? Kinnate Biopharma Inc. (NASDAQ:KNTE) issued its quarterly earnings results on Thursday, May, 11th. The company reported ($0.73) EPS for the quarter, hitting the consensus estimate of ($0.73). When did Kinnate Biopharma IPO? Kinnate Biopharma (KNTE) raised $170 million in an initial public offering (IPO) on Thursday, December 3rd 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, SVB Leerink, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO. What other stocks do shareholders of Kinnate Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kinnate Biopharma investors own include NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Meta Platforms (META), Canopy Growth (CGC) and DraftKings (DKNG). Company Calendar Last Earnings5/11/2023Today9/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:KNTE CIK1797768 Webwww.kinnate.com Phone858-299-4699FaxN/AEmployees84Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$116.27 million Net MarginsN/A Pretax MarginN/A Return on Equity-62.31% Return on Assets-54.72% Debt Debt-to-Equity RatioN/A Current Ratio10.80 Quick Ratio10.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.06 per share Price / Book0.52Miscellaneous Outstanding Shares47,220,000Free Float27,532,000Market Cap$125.13 million OptionableOptionable Beta1.38 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:KNTE) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kinnate Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kinnate Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KNTE Stock Alerts